About BeiGene
BeiGene is a company based in Cambridge (United States) founded in 2010 by John V Oyler. BeiGene has raised $172 million across 6 funding rounds from investors including Merck, Amgen and Fidelity Investments. BeiGene offers products and services including Cancer Therapies. BeiGene operates in a competitive market with competitors including Moderna, Incyte, Vir Biotechnology, Regeneron Pharmaceuticals and MorphoSys, among others.
- Headquarter Cambridge, United States
- Founders John V Oyler
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Beigene, Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$172 M (USD)
in 6 rounds
-
Latest Funding Round
$2.1 B (USD), Post-IPO
Jul 15, 2020
-
Investors
Merck
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BeiGene
BeiGene offers a comprehensive portfolio of products and services, including Cancer Therapies.
Develops treatments for hematology and solid tumors via clinical trials
People of BeiGene
Unlock access to complete
Unlock access to complete
Leadership Team
134 people
Software Development Team
103 people
Operations Team
50 people
Senior Team
49 people
Human Resources and Administration
23 people
Finance and Accounting
20 people
Product Management Team
12 people
Global Team
11 people
Unlock access to complete
Funding Insights of BeiGene
BeiGene has successfully raised a total of $172M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.1 billion completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BeiGene
BeiGene has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Amgen and Fidelity Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Global private equity investments are managed with long-term focus.
|
Locked | Locked | Locked | |
|
Acquisitions are targeted by CPE as a private equity firm.
|
Locked | Locked | Locked |
Investor details for BeiGene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BeiGene
Investment portfolio details for BeiGene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BeiGene
Detailed financials for BeiGene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Beigene Comparisons
Peer comparison for BeiGene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BeiGene
BeiGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Incyte, Vir Biotechnology, Regeneron Pharmaceuticals and MorphoSys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
Detailed competitors of BeiGene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Beigene
Complete news archive for BeiGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BeiGene
BeiGene was founded in 2010 and raised its 1st funding round 1 year after it was founded.
BeiGene is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
John V Oyler is the current CEO of BeiGene. They have also founded this company.
BeiGene is a funded company, having raised a total of $172M across 6 funding rounds to date.
Developer of targeted and immune-oncology drugs against cancer. The companys product pipeline includes oral small molecule inhibitors and monoclonal antibodies, such as BGB-3111, an oral inhibitor of Bruton tyrosine kinase, BGB-283, a B-RAF inhibitor; and BGB-290, a poly (ADP-ribose) polymerase inhibitor. Also, has another candidate BGB-108, a potentially differentiated PD-1 monoclonal antibody candidate.
BeiGene's top competitors include Moderna, Regeneron Pharmaceuticals and Annexon.
BeiGene offers Cancer Therapies.
BeiGene has 10 investors. Key investors include Merck, Amgen, Fidelity Investments, T. Rowe Price, and Rock Springs Capital.